HC Wainwright Predicts Biodesix’s Q3 Earnings (NASDAQ:BDSX)

Biodesix, Inc. (NASDAQ:BDSX) – Equities researchers at HC Wainwright cut their Q3 2026 earnings per share estimates for shares of Biodesix in a research note issued to investors on Thursday, August 6th. HC Wainwright analyst Y. Chen now expects that the company will post earnings of ($0.75) per share for the quarter, down from their previous estimate of ($0.74). HC Wainwright has a “Buy” rating and a $27.00 price objective on the stock. The consensus estimate for Biodesix’s current full-year earnings is ($2.68) per share. HC Wainwright also issued estimates for Biodesix’s Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($2.72) EPS, Q1 2027 earnings at ($0.65) EPS, Q2 2027 earnings at ($0.44) EPS, Q3 2027 earnings at ($0.36) EPS, Q4 2027 earnings at ($0.16) EPS and FY2027 earnings at ($1.57) EPS.

Several other research analysts have also weighed in on the company. Weiss Ratings raised Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 12th. Roth Capital initiated coverage on Biodesix in a report on Wednesday, June 24th. They issued a “buy” rating and a $32.00 price objective for the company. Finally, Canaccord Genuity Group raised their target price on shares of Biodesix from $27.00 to $35.00 and gave the company a “buy” rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $31.33.

Biodesix Price Performance

NASDAQ:BDSX opened at $24.86 on Monday. The stock’s 50-day simple moving average is $19.85 and its 200 day simple moving average is $15.86. Biodesix has a 52-week low of $5.26 and a 52-week high of $25.51. The company has a debt-to-equity ratio of 5.12, a quick ratio of 2.85 and a current ratio of 2.85. The company has a market cap of $262.27 million, a P/E ratio of -7.84 and a beta of 0.56.

Biodesix (NASDAQ:BDSX) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.19. Biodesix had a negative net margin of 26.97% and a negative return on equity of 788.19%. The company had revenue of $26.86 million during the quarter, compared to analysts’ expectations of $26.03 million.

Hedge Funds Weigh In On Biodesix

Institutional investors have recently bought and sold shares of the business. XTX Topco Ltd lifted its position in shares of Biodesix by 99.4% in the second quarter. XTX Topco Ltd now owns 205,647 shares of the company’s stock valued at $58,000 after buying an additional 102,494 shares during the last quarter. Millennium Management LLC acquired a new stake in Biodesix during the 3rd quarter valued at $113,000. Geode Capital Management LLC lifted its holdings in Biodesix by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 42,453 shares of the company’s stock valued at $289,000 after purchasing an additional 2,235 shares during the last quarter. Monashee Investment Management LLC boosted its position in Biodesix by 12.3% during the fourth quarter. Monashee Investment Management LLC now owns 112,344 shares of the company’s stock worth $764,000 after purchasing an additional 12,348 shares during the period. Finally, DRW Securities LLC acquired a new position in shares of Biodesix in the fourth quarter valued at $105,000. Institutional investors and hedge funds own 20.96% of the company’s stock.

About Biodesix

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.